The GPA noted in its commentary on the New York Times article that many companies who are developing biosimilarproducts also manufacture branded biologics.
The companies said the collaboration reflects the shared belief that the development and commercialization of biosimilarproducts will not follow a pure brand or generic model and will require significant expertise, infrastructure and investment to ensure safe, reliably supplied therapies.
Bernstein analyst Ronny Gal, given the proportion of pharmaceutical revenues now generated by biologic products traditional generic drug manufacturers have little choice but to pursue biosimilar development.